1. Home
  2. JBGS vs DBVT Comparison

JBGS vs DBVT Comparison

Compare JBGS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JBG SMITH Properties

JBGS

JBG SMITH Properties

HOLD

Current Price

$14.96

Market Cap

823.7M

Sector

Real Estate

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$17.35

Market Cap

948.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBGS
DBVT
Founded
2016
2002
Country
United States
France
Employees
N/A
90
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
823.7M
948.8M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
JBGS
DBVT
Price
$14.96
$17.35
Analyst Decision
Sell
Buy
Analyst Count
1
7
Target Price
$15.00
$32.04
AVG Volume (30 Days)
627.5K
306.8K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
4.69%
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
$498,598,000.00
$5,636,000.00
Revenue This Year
N/A
$35.04
Revenue Next Year
N/A
$2,360.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.77
52 Week Low
$13.71
$8.51
52 Week High
$24.30
$26.19

Technical Indicators

Market Signals
Indicator
JBGS
DBVT
Relative Strength Index (RSI) 52.31 51.29
Support Level $14.09 $16.05
Resistance Level $15.29 $17.36
Average True Range (ATR) 0.48 1.08
MACD 0.10 0.14
Stochastic Oscillator 60.91 58.10

Price Performance

Historical Comparison
JBGS
DBVT

About JBGS JBG SMITH Properties

JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: